The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Different-dose docetaxel plus cisplatin as first-line chemotherapy and then maintenance therapy with single-agent docetaxel for advanced non-small cell lung cancer (TFINE study, C-TONG 0904).
Li Zhang
Research Funding - AstraZeneca; Bayer; Boehringer Ingelheim; Lilly; Sanofi
Shun Lu
No relevant relationships to disclose
Ying Cheng
No relevant relationships to disclose
Zhihuang Hu
No relevant relationships to disclose
Zhiwei Chen
No relevant relationships to disclose
Gongyan Chen
No relevant relationships to disclose
Xiaoqing Liu
No relevant relationships to disclose
Jinji Yang
No relevant relationships to disclose
Li Zhang
No relevant relationships to disclose
Jia Chen
No relevant relationships to disclose
Meijuan Huang
No relevant relationships to disclose
Min Tao
No relevant relationships to disclose
Gang Cheng
No relevant relationships to disclose
Cheng Huang
No relevant relationships to disclose
Caicun Zhou
No relevant relationships to disclose
Weimin Zhang
No relevant relationships to disclose
Hong Zhao
No relevant relationships to disclose